Dame June Raine

Source: UK Government / Flickr 

The MHRA has published its Corporate Plan for 2023-26, which sets out how it will keep patients safe while enabling access to innovative medical products.

The plan covers the Agency’s central priorities which are:

  • To maintain public trust through transparency and proactive communication.
  • To enable access to safe and effective medical products.
  • To deliver scientific and regulatory excellence through strategic partnerships.
  • To become an Agency where people flourish alongside a responsive customer service culture.

The plan sets out key actions the Agency will take to deliver on these priorities, which it has said will: ‘transform medical product regulation in the UK.’

These range from formalising new recognition pathways for expedited access for medicines, to launching a knowledge hub as a single point of contact to the Agency.

The drug regulator said that patients remain at the heart of its remit. It plans to pilot public awareness activities to increase patient understanding of the Agency’s benefit-risk decisions as well as public hearings on major safety issues, so that patient and stakeholder experiences can be considered.

“We will transform our regulatory processes, making the UK an attractive home for the global life sciences industry and a place where medical innovation can flourish, so all patients can benefit from the very latest in safe and effective medical products,” said Dame June Raine, MHRA Chief Executive.

Further reading:

MHRA Corporate Plan 2023 to 2026: